Brief: Vanda Pharmaceuticals Announces Positive Phase III Results For Hetlioz®(Tasimelteon) In Delayed Sleep-Wake Phase Disorder
29/09/2026 23:47
BRIEF-Vanda Pharmaceuticals Announces Positive Phase III Results For Hetlioz®(Tasimelteon) In Delayed Sleep-Wake Phase Disorder Sept 29 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:
VANDA PHARMACEUTICALS ANNOUNCES POSITIVE PHASE III RESULTS FOR HETLIOZ®(TASIMELTEON) IN DELAYED SLEEP-WAKE PHASE DISORDER
VANDA PHARMACEUTICALS - PHASE III STUDY MET PRIMARY ENDPOINT WITH 37.1 MINUTE SLEEP ONSET SHIFT VERSUS PLACEBO
VANDA PHARMACEUTICALS - NO NEW SAFETY SIGNALS IDENTIFIED IN PHASE III STUDY FOR HETLIOZ
Source text: ID:nPncdwbnCa
Further company coverage: VNDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program